Skip to main content
Signal8
Launch Terminal

LENZ Therapeutics, Inc. (LENZ)

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc.

NASDAQ:LENZHealthcare
-12.61%$3.05
AH$3.09+1.31%vs close
Mkt Cap$95.83M
Float–
O/S31.42M
Vol
$ Vol
RVOL
Inst Own-
Earnings
Dilution
LENZ Therapeutics, Inc. logoNASDAQ:LENZ$3.05-12.61%
FormDescription
8-K
2.02,2.05,5.02,9.01
5
13G
Beneficial Ownership Report
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
10-Q
Quarterly Report
6
8-K
2.02,9.01
4
8-K
5.02
13G
Beneficial Ownership Report
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership
8-K
5.07
1
10-Q
Quarterly Report
8-K
2.02,9.01
1
ARS
SEC Filing
DEFA14A
Additional Proxy Materials
DEF 14A
Definitive Proxy Statement
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
4
Statement of Changes in Beneficial Ownership
4
Statement of Changes in Beneficial Ownership

1-25 of 353

…

Recent SEC filings with analysis